The End Drug Shortages Alliance appointed Terri Lyle Wilson as its new chair and appointed two board members Jan. 23. 

North Carolina's state health plan dropped new coverage for weight loss drugs Jan. 1, a decision that is expected to cost the state $54 million in lost drug rebates, WRAL News reported Jan. 12.

Some Blue Cross Blue Shield companies now cover two newly approved sickle cell gene therapies, which cost about $2 million and $3 million per dose. 

During a visit last summer, FDA inspectors flagged eight deficiencies at an Eli Lilly manufacturing plant in Branchburg, N.J., according to an inspection report Reuters obtained through a Freedom of Information Act Request. 

Despite their rise to popularity as solutions for weight loss, drugs like Ozempic and Wegovy can also lead to muscle loss, and now pharmaceutical companies are looking at ways to curb the unwanted side effect, according to The Wall Street…

Physicians, drugmakers, obesity organizations and the FDA are fretting about compounded versions of popular weight loss and diabetes drugs, including Wegovy, Ozempic and Zepbound. 

Washington, D.C.-based Children's National Hospital administered Zynteglo, a $2.8 million gene therapy, to its first pediatric patient with the help of Clearway Health. 

The bone disease drug Prolia has a new boxed warning, the FDA's most prominent warning, because of an increased risk of severe hypocalcemia among chronic kidney disease patients. 

Hospitals should start conserving supply of short-term anesthetics as drug manufacturers become more conservative with nitrosamine measures, according to Eric Tichy, PharmD. 

Former health system pharmacy leader Shawn Parekh, PharmD, recently became CEO of a Philadelphia hospital.